EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieValidierungsstudieKlinische Studie (Phase II)Open Access · CC BY 4.0

The first validation of the Functional Assessment of Cancer Therapy Hepatobiliary (FACT-Hep) for evaluating health-related quality of life (HRQOL) in patients with advanced-stage intrahepatic cholangiocarcinoma (biliary tract cancer)

Teerachat Saeheng, Nisit Tongsiri, Kesara Na-Bangchang iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0321618 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2025. Verfasst von Teerachat Saeheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College, Thammasat University …. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Cholangiocarcinoma, Quality of Life. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Thailand Science Research and Innovation Fundamental Fund Fiscal Year 2023, Thammasat University, National Research Council of Thailand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The FACT-Hep questionnaire has been used to evaluate the health-related quality of life (HRQOL) in various types of hepatobiliary cancer. Nevertheless, the application in intrahepatic cholangiocarcinoma (iCCA) has been limited. The study aimed to validate the applicability of FACT-Hep as a reliable tool for evaluating HRQOL in patients with advanced-stage iCCA.

Methods

Atractylodes lancea capsules were tested for efficacy and safety in a randomized, controlled phase IIA. Internal consistency, intraclass correlation, test-retest reliability, discriminant and convergent validity, and FACT-Hep score-clinical response connection were assessed.

Results

Thirty-nine patients qualified for the research. Cronbach’s alpha coefficients > 0.7 showed internal consistency for all subscale items from baseline (day 1) to 90 days. For ICC, convergent, and discriminant validity, all items except the HepCS subscale were reliable. Patients with ECOG scores of 0–1 or 2 had significantly different HepCS subscale values—calculated effect size for subscale score change over time. FACT-G and FWB differed significantly in low-dose group 1. At 3-month, 1-month, and 2-month follow-ups, Group 2 (high dose) patients had significant differences in FACT-Hep, TOI, and HepCS. The effect size was the same in Group 3 (untreated). Group 1 and 2 non-progressive patients exhibited lower FWB and EWB scores than progressive patients. The treated survivors had lower FACT-Hep, TOI, HepCS, FWB, and EWB scores than the non-treated survivors, which was linked to AL treatment side effects.

Conclusion

The FACT-Hep detects changes and is a reliable and valid tool for assessing HRQOL in patients with advanced-stage iCCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bile Duct NeoplasmsCholangiocarcinomaQuality of LifeAdultAgedFemaleHumansMaleMiddle AgedReproducibility of ResultsSurveys and QuestionnairesAtractylodesPlant Preparations

Substanzen

Plant Preparations

Autor:innen und Institutionen

  • Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College, Thammasat University (Rangsit Campus), Klongneung District, Pathumthani Province, Thailand.
  • Sakol Nakorn Hospital, Muang District, Sakol Nakorn Province, Thailand.
  • Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University (Rangsit Campus), Klongneung District, Pathumthani Province, Thailand.

ORCID-Profile: Kesara Na-Bangchang

Förderung

  • Thailand Science Research and Innovation Fundamental Fund Fiscal Year 2023
  • Thammasat University
  • National Research Council of Thailand

Zitieren

APA

Saeheng, T., Tongsiri, N., & Na-Bangchang, K. (2025). The first validation of the Functional Assessment of Cancer Therapy Hepatobiliary (FACT-Hep) for evaluating health-related quality of life (HRQOL) in patients with advanced-stage intrahepatic cholangiocarcinoma (biliary tract cancer). PLOS One. https://doi.org/10.1371/journal.pone.0321618

Vancouver

Saeheng T, Tongsiri N, Na-Bangchang K. The first validation of the Functional Assessment of Cancer Therapy Hepatobiliary (FACT-Hep) for evaluating health-related quality of life (HRQOL) in patients with advanced-stage intrahepatic cholangiocarcinoma (biliary tract cancer). PLOS One. 2025. doi:10.1371/journal.pone.0321618

BibTeX
@article{Saeheng2025,
  author = {Saeheng, Teerachat and Tongsiri, Nisit and Na-Bangchang, Kesara},
  title = {The first validation of the Functional Assessment of Cancer Therapy Hepatobiliary (FACT-Hep) for evaluating health-related quality of life (HRQOL) in patients with advanced-stage intrahepatic cholangiocarcinoma (biliary tract cancer)},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0321618}
}
Kostenlos starten →